Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women

Matthew M Drake, Bhuma Srinivasan, Ulrike I. Mödder, James M. Peterson, Louise K. McCready, B. Lawrence Riggs, Denise Dwyer, Marina Stolina, Paul Kostenuik, Sundeep Khosla

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Context: Intermittent PTH treatment stimulates bone formation, but the mechanism(s) of this effect remain unclear. Sclerostin is an inhibitor of Wnt signaling, and animal studies have demonstrated that PTH suppresses sclerostin production. Objective: The objective of the study was to test whether intermittent PTH treatment of postmenopausal women alters circulating sclerostin levels. Design: Prospective study. Setting: The study was conducted at a clinical research unit. Participants and Interventions: Participants included 27 postmenopausal women treated with PTH (1-34) for 14 d and 28 control women. Main Outcome Measures: Serum sclerostin levels were measured. Results: Circulating sclerostin levels decreased significantly in the PTH-treated subjects, from (mean ± SEM) 551 ± 32 to 482 ± 31 pg/ml (-12.7%, P < 0.0001) but did not change in the control women (baseline, 559 ± 34 pg/ml; end point, 537 ± 40 pg/ml, P = 0.207; P = 0.017 for difference in changes between groups). Bone marrow plasma was obtained in a subset of the control and PTH-treated subjects (n = 19 each) at the end of the treatment period, and marrow plasma and peripheral serum sclerostin levels were significantly correlated (R = 0.64, P < 0.0001). Marrow plasma sclerostin levels were 24% lower in PTH-treated compared with control women, but perhaps due to the smaller sample size, this difference was not statistically significant (P = 0.173). Conclusions: Circulating sclerostin levels correlate with bone marrow plasma levels and are reduced by intermittent PTH therapy in postmenopausal women. Further studies are needed to assess the extent to which decreases in sclerostin production contribute to the anabolic skeletal response to PTH.

Original languageEnglish (US)
Pages (from-to)5056-5062
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume95
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Parathyroid Hormone
Plasmas
Bone
Bone Marrow
Therapeutics
Animals
Serum
Osteogenesis
Sample Size
Scanning electron microscopy
Outcome Assessment (Health Care)
Prospective Studies
Research

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. / Drake, Matthew M; Srinivasan, Bhuma; Mödder, Ulrike I.; Peterson, James M.; McCready, Louise K.; Riggs, B. Lawrence; Dwyer, Denise; Stolina, Marina; Kostenuik, Paul; Khosla, Sundeep.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 95, No. 11, 11.2010, p. 5056-5062.

Research output: Contribution to journalArticle

Drake, MM, Srinivasan, B, Mödder, UI, Peterson, JM, McCready, LK, Riggs, BL, Dwyer, D, Stolina, M, Kostenuik, P & Khosla, S 2010, 'Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women', Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 11, pp. 5056-5062. https://doi.org/10.1210/jc.2010-0720
Drake, Matthew M ; Srinivasan, Bhuma ; Mödder, Ulrike I. ; Peterson, James M. ; McCready, Louise K. ; Riggs, B. Lawrence ; Dwyer, Denise ; Stolina, Marina ; Kostenuik, Paul ; Khosla, Sundeep. / Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. In: Journal of Clinical Endocrinology and Metabolism. 2010 ; Vol. 95, No. 11. pp. 5056-5062.
@article{5767f9819cc44f72947ae49239d6a726,
title = "Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women",
abstract = "Context: Intermittent PTH treatment stimulates bone formation, but the mechanism(s) of this effect remain unclear. Sclerostin is an inhibitor of Wnt signaling, and animal studies have demonstrated that PTH suppresses sclerostin production. Objective: The objective of the study was to test whether intermittent PTH treatment of postmenopausal women alters circulating sclerostin levels. Design: Prospective study. Setting: The study was conducted at a clinical research unit. Participants and Interventions: Participants included 27 postmenopausal women treated with PTH (1-34) for 14 d and 28 control women. Main Outcome Measures: Serum sclerostin levels were measured. Results: Circulating sclerostin levels decreased significantly in the PTH-treated subjects, from (mean ± SEM) 551 ± 32 to 482 ± 31 pg/ml (-12.7{\%}, P < 0.0001) but did not change in the control women (baseline, 559 ± 34 pg/ml; end point, 537 ± 40 pg/ml, P = 0.207; P = 0.017 for difference in changes between groups). Bone marrow plasma was obtained in a subset of the control and PTH-treated subjects (n = 19 each) at the end of the treatment period, and marrow plasma and peripheral serum sclerostin levels were significantly correlated (R = 0.64, P < 0.0001). Marrow plasma sclerostin levels were 24{\%} lower in PTH-treated compared with control women, but perhaps due to the smaller sample size, this difference was not statistically significant (P = 0.173). Conclusions: Circulating sclerostin levels correlate with bone marrow plasma levels and are reduced by intermittent PTH therapy in postmenopausal women. Further studies are needed to assess the extent to which decreases in sclerostin production contribute to the anabolic skeletal response to PTH.",
author = "Drake, {Matthew M} and Bhuma Srinivasan and M{\"o}dder, {Ulrike I.} and Peterson, {James M.} and McCready, {Louise K.} and Riggs, {B. Lawrence} and Denise Dwyer and Marina Stolina and Paul Kostenuik and Sundeep Khosla",
year = "2010",
month = "11",
doi = "10.1210/jc.2010-0720",
language = "English (US)",
volume = "95",
pages = "5056--5062",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women

AU - Drake, Matthew M

AU - Srinivasan, Bhuma

AU - Mödder, Ulrike I.

AU - Peterson, James M.

AU - McCready, Louise K.

AU - Riggs, B. Lawrence

AU - Dwyer, Denise

AU - Stolina, Marina

AU - Kostenuik, Paul

AU - Khosla, Sundeep

PY - 2010/11

Y1 - 2010/11

N2 - Context: Intermittent PTH treatment stimulates bone formation, but the mechanism(s) of this effect remain unclear. Sclerostin is an inhibitor of Wnt signaling, and animal studies have demonstrated that PTH suppresses sclerostin production. Objective: The objective of the study was to test whether intermittent PTH treatment of postmenopausal women alters circulating sclerostin levels. Design: Prospective study. Setting: The study was conducted at a clinical research unit. Participants and Interventions: Participants included 27 postmenopausal women treated with PTH (1-34) for 14 d and 28 control women. Main Outcome Measures: Serum sclerostin levels were measured. Results: Circulating sclerostin levels decreased significantly in the PTH-treated subjects, from (mean ± SEM) 551 ± 32 to 482 ± 31 pg/ml (-12.7%, P < 0.0001) but did not change in the control women (baseline, 559 ± 34 pg/ml; end point, 537 ± 40 pg/ml, P = 0.207; P = 0.017 for difference in changes between groups). Bone marrow plasma was obtained in a subset of the control and PTH-treated subjects (n = 19 each) at the end of the treatment period, and marrow plasma and peripheral serum sclerostin levels were significantly correlated (R = 0.64, P < 0.0001). Marrow plasma sclerostin levels were 24% lower in PTH-treated compared with control women, but perhaps due to the smaller sample size, this difference was not statistically significant (P = 0.173). Conclusions: Circulating sclerostin levels correlate with bone marrow plasma levels and are reduced by intermittent PTH therapy in postmenopausal women. Further studies are needed to assess the extent to which decreases in sclerostin production contribute to the anabolic skeletal response to PTH.

AB - Context: Intermittent PTH treatment stimulates bone formation, but the mechanism(s) of this effect remain unclear. Sclerostin is an inhibitor of Wnt signaling, and animal studies have demonstrated that PTH suppresses sclerostin production. Objective: The objective of the study was to test whether intermittent PTH treatment of postmenopausal women alters circulating sclerostin levels. Design: Prospective study. Setting: The study was conducted at a clinical research unit. Participants and Interventions: Participants included 27 postmenopausal women treated with PTH (1-34) for 14 d and 28 control women. Main Outcome Measures: Serum sclerostin levels were measured. Results: Circulating sclerostin levels decreased significantly in the PTH-treated subjects, from (mean ± SEM) 551 ± 32 to 482 ± 31 pg/ml (-12.7%, P < 0.0001) but did not change in the control women (baseline, 559 ± 34 pg/ml; end point, 537 ± 40 pg/ml, P = 0.207; P = 0.017 for difference in changes between groups). Bone marrow plasma was obtained in a subset of the control and PTH-treated subjects (n = 19 each) at the end of the treatment period, and marrow plasma and peripheral serum sclerostin levels were significantly correlated (R = 0.64, P < 0.0001). Marrow plasma sclerostin levels were 24% lower in PTH-treated compared with control women, but perhaps due to the smaller sample size, this difference was not statistically significant (P = 0.173). Conclusions: Circulating sclerostin levels correlate with bone marrow plasma levels and are reduced by intermittent PTH therapy in postmenopausal women. Further studies are needed to assess the extent to which decreases in sclerostin production contribute to the anabolic skeletal response to PTH.

UR - http://www.scopus.com/inward/record.url?scp=77957853500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957853500&partnerID=8YFLogxK

U2 - 10.1210/jc.2010-0720

DO - 10.1210/jc.2010-0720

M3 - Article

C2 - 20631014

AN - SCOPUS:77957853500

VL - 95

SP - 5056

EP - 5062

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -